Cross-Sector entity
Of the tracked stories, 3 of 6 also mention Keros Therapeutics, the most common co-covered peer. market-trends accounts for 3 of the 6 tracked stories, while 3 other categories carry the remainder. We currently track 6 Cross-Sector stories that mention Amprius Technologies, published between March 4, 2026 and March 6, 2026.
6 verified stories tracked
Last mentioned: Mar 6, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 6 also mention Keros Therapeutics, the most common co-covered peer. market-trends accounts for 3 of the 6 tracked stories, while 3 other categories carry the remainder. We currently track 6 Cross-Sector stories that mention Amprius Technologies, published between March 4, 2026 and March 6, 2026. 0% of these stories carry negative sentiment. The tracked stories average 5 original sources each.
Computed from the 6 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Amprius Technologies. Shared-story counts are live from our verified record — not editorial picks.
FY 2025 Earnings
Released full-year financial results and updated 2026 clinical guidance.
FY2025 Earnings
Released full-year results highlighting commercial scaling and Colorado facility progress.
Anticipated Data
Expected top-line data readouts for multiple Phase 2 programs.
Brighton Fab Launch
Expected commencement of high-volume manufacturing in Colorado.
Cibotercept Progress
Initiated additional cohorts in PAH studies to evaluate dose-response.
KER-050 Expansion
Initiation of the global Phase 2/3 trial for elritercept in lower-risk MDS.
500 Wh/kg Milestone
Verified performance of 500 Wh/kg cells with key aerospace partners.
Trial Expansion
Keros expanded the TROPOS trial to include broader MDS patient populations.
Capital Infusion
Keros raised $140 million in a follow-on offering to fund late-stage TGF-beta trials.
Industrial leaders in sustainable packaging and advanced energy reported robust Q4 2025 results, driven by a surge in data center power demand and high-density battery technology. The convergence of automation and NDAA-compliant energy storage is signaling a significant maturation of the green industrial economy.
Industrial and logistics providers are pivoting toward high-margin automation and domestic-compliant sourcing to navigate a bifurcated global economy. While North American demand for automated packaging and specialized power solutions remains robust, regulatory constraints and regional weakness in Europe continue to challenge traditional shipping and bunkering segments.
Amprius Technologies has achieved full NDAA compliance for its silicon anode battery supply chain while expanding its Defense Innovation Unit contract to $14.8 million. Concurrently, Stabilis Solutions reported a 17% surge in aerospace revenue, driven by heightened commercial launch activity and a strategic shift toward defense-adjacent infrastructure.
Amprius Technologies reported its full-year 2025 financial results, highlighting a critical transition from pilot-scale production to industrial commercialization of its high-energy silicon anode batteries. The company is positioning its ultra-high-density storage solutions as the primary enabler for the burgeoning eVTOL and defense aviation sectors.
Keros Therapeutics reported robust fourth-quarter and full-year 2025 financial results, highlighting significant clinical progress across its TGF-β superfamily pipeline. The company remains well-capitalized to advance its lead assets, elritercept and cibotercept, through critical Phase 2 and Phase 3 milestones in 2026.
Keros Therapeutics reported its full-year 2025 results, highlighting significant clinical progress in its TGF-β protein superfamily pipeline for hematologic and cardiovascular disorders. The company maintains a robust cash position to fund pivotal trials for elritercept and cibotercept through key upcoming data readouts in 2026.
Source: lasvegassun.com · manilatimes.net
